IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma announces the publication of an interview with CEO Ram Mukunda in the IMS Spotlight Series. The interview highlights the company's strategic expansion into metabolic and neurological markets, focusing on GLP-1 agonists for both Alzheimer's and weight loss therapies. Mukunda discusses updates on IGC-AD1, their lead candidate currently in Phase 2 trials for treating agitation in Alzheimer's dementia, which is advancing toward additional trials for potential disease-modifying treatment. The company emphasizes its use of artificial intelligence to diversify its pipeline across neurodegenerative and metabolic disorders.
IGC Pharma annuncia la pubblicazione di un'intervista con il CEO Ram Mukunda nella serie IMS Spotlight. L'intervista mette in evidenza l'espansione strategica dell'azienda nei mercati metabolici e neurologici, concentrandosi sugli agonisti del GLP-1 sia per le terapie contro l'Alzheimer che per la perdita di peso. Mukunda discute gli aggiornamenti su IGC-AD1, il loro candidato principale attualmente in fase 2 di sperimentazione per il trattamento dell'agitazione nella demenza di Alzheimer, avanzando verso ulteriori trial per un potenziale trattamento modificante la malattia. L'azienda sottolinea l'uso dell'intelligenza artificiale per diversificare il proprio portafoglio in relazione ai disturbi neurodegenerativi e metabolici.
IGC Pharma anuncia la publicación de una entrevista con el CEO Ram Mukunda en la serie IMS Spotlight. La entrevista resalta la expansión estratégica de la compañía en los mercados metabólicos y neurológicos, con un enfoque en los agonistas del GLP-1 para las terapias contra el Alzheimer y la pérdida de peso. Mukunda discute las actualizaciones sobre IGC-AD1, su candidato principal que actualmente se encuentra en ensayos de Fase 2 para tratar la agitación en la demencia de Alzheimer, avanzando hacia ensayos adicionales para un posible tratamiento modificador de la enfermedad. La compañía enfatiza su uso de inteligencia artificial para diversificar su cartera en trastornos neurodegenerativos y metabólicos.
IGC Pharma는 CEO Ram Mukunda와의 인터뷰가 IMS Spotlight 시리즈에 게재되었다고 발표했습니다. 이 인터뷰는 회사의 대사 및 신경학적 시장으로의 전략적 확장을 강조하며, 알츠하이머 및 체중 감소 치료를 위한 GLP-1 작용제에 중점을 두고 있습니다. Mukunda는 알츠하이머 치매의 동요 치료를 위해 현재 2상 시험 중인 주요 후보 물질인 IGC-AD1에 대한 업데이트를 논의하며, 질병 수정 치료를 위한 추가 시험으로 나아가고 있습니다. 이 회사는 신경퇴행성 및 대사 장애에 걸쳐 파이프라인을 다양화하기 위해 인공지능을 사용하고 있음을 강조합니다.
IGC Pharma annonce la publication d'une interview avec le PDG Ram Mukunda dans la série IMS Spotlight. L'interview met en avant l'expansion stratégique de l'entreprise sur les marchés métaboliques et neurologiques, en se concentrant sur les agonistes du GLP-1 pour les thérapies contre la maladie d'Alzheimer et la perte de poids. Mukunda discute des mises à jour sur IGC-AD1, leur candidat principal actuellement en phase 2 d'essai pour le traitement de l'agitation dans la démence d'Alzheimer, qui avance vers des essais supplémentaires pour un traitement potentiel modifiant la maladie. L'entreprise souligne son utilisation de l'intelligence artificielle pour diversifier son pipeline dans les troubles neurodégénératifs et métaboliques.
IGC Pharma kündigt die Veröffentlichung eines Interviews mit CEO Ram Mukunda in der IMS Spotlight-Serie an. Das Interview hebt die strategischeExpansion des Unternehmens in die metabolischen und neurologischen Märkte hervor, wobei der Fokus auf GLP-1-Agonisten für Therapien gegen Alzheimer und zur Gewichtsreduktion liegt. Mukunda diskutiert Aktualisierungen zu IGC-AD1, ihrem führenden Kandidaten, der derzeit in Phase-2-Studien zur Behandlung von Erregung bei Alzheimer-Demenz ist und auf weitere Studien für mögliche krankheitsmodifizierende Behandlungen hinarbeitet. Das Unternehmen betont den Einsatz von künstlicher Intelligenz zur Diversifizierung seiner Pipeline in Bezug auf neurodegenerative und metabolische Störungen.
- Lead candidate IGC-AD1 progressing in Phase 2 trials for Alzheimer's agitation
- Strategic expansion into additional therapeutic areas (weight loss)
- Potential for IGC-AD1 as a disease-modifying treatment for Alzheimer's
- None.
POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series.
In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies. Mukunda also provides updates on IGC Pharma's lead candidate, IGC-AD1, which is currently in Phase 2 trials for treating agitation in Alzheimer's dementia and is progressing toward additional trials to explore its potential as a disease-modifying treatment.
The interview underscores IGC's approach to leveraging artificial intelligence to diversify its pipeline, targeting both neurodegenerative and metabolic disorders to maximize patient impact.
To read the full interview, please visit: Expanding Our Portfolio: IGC Pharma's Strategic Growth in Alzheimer's and Weight Loss Therapies
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
Forward-looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information:
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on accesswire.com
FAQ
What is IGC Pharma's lead drug candidate IGC-AD1 currently being tested for?
What new therapeutic areas is IGC Pharma (IGC) expanding into?